128 related articles for article (PubMed ID: 9389366)
1. Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
Garay G; Dupont J; Dragosky M; Nucifora E; Cacchione R; Schnidrig P; Fernández J; Abel-Alzueta ; Riveros D; Noviello V; Bèguelin R; Campestri R; Albera C; Nicastro M; Triguboff E
Leuk Lymphoma; 1997 Aug; 26(5-6):595-602. PubMed ID: 9389366
[TBL] [Abstract][Full Text] [Related]
2. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
Reiser M; Schnell R; Straub G; Borchmann P; Wilhelm M; Ubelacker R; Wörmann B; Münch R; Diehl V; Engert A
Leuk Lymphoma; 1998 Oct; 31(3-4):359-66. PubMed ID: 9869200
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
5. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M; Leonard J; Shuster MW; Kaufman TP
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[TBL] [Abstract][Full Text] [Related]
6. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Rodriguez MA; Cabanillas FC; Velasquez W; Hagemeister FB; McLaughlin P; Swan F; Romaguera JE
J Clin Oncol; 1995 Jul; 13(7):1734-41. PubMed ID: 7602363
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F
Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540
[TBL] [Abstract][Full Text] [Related]
8. A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
Engert A; Schnell R; Küpper F; Reiser M; Engelhard M; Wilhelm M; Lathan B; Baltes-Engler S; Winterhalter B; Scheulen ME; Dederichs B; Tesch H; Wörmann B; Diehl V
Leuk Lymphoma; 1997 Feb; 24(5-6):513-22. PubMed ID: 9086441
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma.
Hopfinger G; Heinz R; Koller E; Schneider B; Pittermann E
Eur J Haematol; 1995 Oct; 55(4):223-7. PubMed ID: 7589338
[TBL] [Abstract][Full Text] [Related]
10. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
15. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Romaguera JE; Hagemeister FB; McLaughlin P; Rodriguez MA; Bachier C; Preti H; Sarris AH; Weber D; Younes A; Cabanillas F
Leuk Lymphoma; 1998 Dec; 32(1-2):97-106. PubMed ID: 10037005
[TBL] [Abstract][Full Text] [Related]
16. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Itoh K; Igarashi T; Ohtsu T; Wakita H; Watanabe Y; Fujii H; Minami H; Sasaki Y
Int J Hematol; 1998 Dec; 68(4):431-7. PubMed ID: 9885442
[TBL] [Abstract][Full Text] [Related]
18. IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
Abali H; Oyan B; Koc Y; Kars A; Barista I; Uner A; Turker A; Demirkazik F; Tekin F; Tekuzman G; Kansu E
Am J Clin Oncol; 2005 Jun; 28(3):264-9. PubMed ID: 15923799
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
Salman H; Perez A; Sparano JA; Ratech H; Negassa A; Hopkins U; Villani G; Fuks J; Wiernik PH
Am J Clin Oncol; 2003 Aug; 26(4):338-43. PubMed ID: 12902881
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
